Companies Dominating the CRISPR & Cas Genes Landscape
- Thermo Fisher Scientific
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Illumina
- Agilent Technologies
- Synthego
- Danaher
- Origene Technologies
- GenScript
- Lonza
- Revvity, Inc.
- Merck KGaA
- Mammoth Biosciences, Inc.
- Regeneron Pharmaceuticals, Inc.
Considering the higher utility in the medical industry, key players are majorly focused on engaging their offerings in the pharmaceutical segment in the CRISPR & cas genes market. They are actively developing new applications and therapeutics for wider adoption. For instance, in January 2024, CRISPR Therapeutics attained FDA approval for using CASGEVY (exagamglogene autotemcel) as a streamlined curative for transfusion-dependent beta-thalassemia. This CRISPR/Cas9 gene-edited cell therapy has been proven to be highly effective for residents aged 12 and over. Simultaneously, many other biopharmaceutical pioneers are participating in this cohort by introducing more efficient approaches. Such key players are CRISPR & cas genes market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
CRISPR & Cas Genes Market in 2025 is evaluated at USD 5.54 billion.
The global market size was valued at over USD 4.9 billion in 2024 and is expected to expand at a CAGR of around 16.4%, surpassing USD 35.28 billion revenue by 2037.
North America is set to exceed USD 15.59 billion by 2037, fueled by its excellence in genomic alterations, clinical data sharing, and drug discovery.
The major players in the market include Merck KGaA, GenScript, Lonza, Agilent Technologies, Illumina, Thermo Fisher Scientific, and others.
